Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 1 1

Status

Withdrawn 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Lymphoid 1

Conditions

Leukemia, Lymphocytic, Chronic, B-Cell 3Lymphoma, Follicular 2Recurrence 1Lymphoma, T-Cell, Peripheral 1Lymphoma, B-Cell, Marginal Zone 1Lymphoma 1Immunoblastic Lymphadenopathy 1Hereditary Sensory and Autonomic Neuropathies 1

Interventions

Rituximab 23Cyclophosphamide 11Radiotherapy 8Prednisone 8Vincristine 7Doxorubicin 7Lenalidomide 6Bendamustine Hydrochloride 5Chlorambucil 4Peripheral Blood Stem Cell Transplantation 3Filgrastim 3obinutuzumab 2liposomal amphotericin B 2idelalisib 2ibrutinib 2fludarabine phosphate 2VAP-cyclo protocol 2Therapeutics 2Psychiatric Rehabilitation 2Levofloxacin 2Interferon-alpha 2Idarubicin 2Epoetin Alfa 2Early Intervention, Educational 2Cyclosporine 2Busulfan 2zanubrutinib 1tafasitamab 1parsaclisib 1orelabrutinib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 3 × Lymphoma, B-Cell, Marginal Zone × duvelisib × Clear all
NCT02576275 2021-03-17

A Study of Duvelisib in Combination With Rituximab and Bendamustine vs Placebo in Combination With Rituximab and Bendamustine in Subjects With Previously-Treated Indolent Non-Hodgkin Lymphoma (BRAVURA)

SecuraBio

Phase 3 Withdrawn
LymphoidOther hematologic neoplasm

Lymphoma, Follicular, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, B-Cell, Marginal Zone

Data powered by HemOnc (CC BY 4.0) Colophon âš¡